Recent 8-K filings for ALMS
Highest-materiality recent filing
Alumis Phase 3 oral psoriasis drug envudeucitinib meets all endpoints; NDA planned H2 2026
- Both ONWARD1 and ONWARD2 trials met co-primary endpoints PASI 75 and sPGA 0/1 at Week 16 (p<0.0001).
- At Week 24, ~65% achieved PASI 90 and >40% PASI 100, on average across trials.
-
Alumis LUMUS Phase 2b misses primary endpoint in SLE; IFNGS-high subgroup shows robust responses
LUMUS Phase 2b (n=408) did not meet primary endpoint BICLA at Week 48 in overall SLE population.
-
Alumis Q2 2026: ONWARD3 shows 54% PASI 100; NDA on track for Q4
ONWARD3: 75% PASI 90, 54% PASI 100 at 48 weeks (n=773) for envudeucitinib in PsO.
-
Envudeucitinib achieves 54% PASI 100 at 48 weeks; NDA on track for 4Q 2026
54% of patients achieved PASI 100 (complete skin clearance) at 48 weeks; 75% achieved PASI 90.
-
Elected James B. Tananbaum, Lynn Tetrault, and Zhengbin Yao as Class II directors for terms expiring 2029.
-
Alumis posts corporate presentation update; no material new data disclosed in filing
Filed a June 2026 corporate deck under Item 8.01 for investor meetings.
-
Alumis Q1 net loss $93.1M; Phase 3 envudeucitinib shows 68% PASI 90; NDA on track Q4 2026
Net loss $93.1M for Q1 2026; cash, equivalents and marketable securities $569.5M; runway into Q4 2027.
-
Alumis Phase 3 envudeucitinib hits PASI 90/100 endpoints in plaque psoriasis
PASI 90 at Week 24: 68.0% (ONWARD1) and 62.1% (ONWARD2); PASI 100: 41.0% and 39.5%.
-
Alumis reports 2025 net loss $243.3M; Phase 3 envudeucitinib meets endpoints; NDA plan 2H2026
Net loss of $243.3M vs. $294.2M in 2024; revenue $24.1M from Kaken license.
-
Alumis prices public offering of 17.65M shares at $17/sh for ~$345M gross; prelim cash $308.6M
Public offering of 17,650,000 shares at $17.00 per share; gross proceeds ~$345.1 million.
-
Alumis Phase 3 oral psoriasis drug envudeucitinib meets all endpoints; NDA planned H2 2026
Both ONWARD1 and ONWARD2 trials met co-primary endpoints PASI 75 and sPGA 0/1 at Week 16 (p<0.0001).
-
Climb Bio failed to pay $3,000,000 Development Milestone due Jan 1, 2026 under the Asset Purchase Agreement.
-
Alumis Q3 net loss $110.8M; cash $377.7M; Phase 3 psoriasis data expected Q1 2026
Net loss of $110.8M for Q3 2025 vs. $93.1M in Q3 2024; R&D expenses rose to $97.8M from $87.8M.
-
Alumis releases updated September 2025 corporate presentation
Company filed updated corporate presentation dated September 2025 for use with investors.
-
Cash, cash equivalents and marketable securities of $486.3M as of June 30, 2025; expects to fund operations into 2027.
-
Alumis stockholders elect two Class I directors, ratify PwC as auditor
Srinivas Akkaraju (55,095,965 for) and Sapna Srivastava (54,546,203 for) elected Class I directors.
-
Alumis files ACELYRIN financials: 2024 net loss $248M, cash $448M
ACELYRIN's FY2024 net loss $248.2M, down from $381.6M in 2023; no revenue.
-
Alumis completes merger with ACELYRIN; cash runway extended into 2027
Each ACELYRIN share exchanged for 0.4814 shares of Alumis common stock; ACELYRIN stock ceased trading.
-
Alumis shareholders approve ACELYRIN merger; expected to close May 21, 2025
Stock issuance proposal approved: 41,861,422 For, 159,077 Against, 1,406 Abstain.
-
Alumis Q1 net loss $99M, revenue $17.4M; merger with ACELYRIN on track for Q2 2025 close
Net loss of $99M in Q1 2025 vs $49.8M in Q1 2024; revenue of $17.4M from Kaken license fee.
-
Alumis and ACELYRIN amend merger terms; ACELYRIN stockholders get 48% ownership of combined company
Exchange ratio revised to 0.4814 Alumis shares per ACELYRIN share, up from original terms; Alumis stockholders own ~52%, ACELYRIN ~48% fully diluted.
-
Alumis licenses ESK-001 to Kaken for Japan; $40M upfront/near-term plus $140M milestones
Alumis receives $20M upfront and $20M co-development payments from Kaken in 2025-2026.
-
Alumis 2024 net loss $294.2M, cash $288.3M; ACELYRIN merger expected Q2 2025
Net loss of $294.2M in 2024 vs $155.0M in 2023; R&D expenses rose to $265.6M from $137.7M.
-
Alumis and ACELYRIN release merger presentation update (limited details)
Alumis and ACELYRIN released an updated merger presentation on March 18, 2025 (original announcement Feb 6, 2025).
-
Alumis reports positive 52-week Phase 2 OLE data for ESK-001 in plaque psoriasis at AAD 2025
ESK-001 40 mg BID achieved PASI 90 61.3%, PASI 100 38.8%, sPGA 0 38.8% at Week 52 (mNRI, n=80).
-
Alumis and ACELYRIN reaffirm all-stock merger; pro forma cash ~$737M
Alumis and ACELYRIN reaffirm commitment to merge in an all-stock transaction expected to close Q2 2025.
-
Plan provides cash severance of 6-18 months base salary (plus 1-1.5x target bonus) for qualifying terminations within 12 months of a change of control.
-
Alumis to acquire ACELYRIN in all-stock merger; exchange ratio 0.4274
Alumis to acquire ACELYRIN via merger; each ACELYRIN share converted into 0.4274 Alumis shares.
-
Alumis updates LUMUS Phase 2 trial timeline on ClinicalTrials.gov
Revised primary completion and study completion dates for LUMUS trial (ESK-001 in SLE) posted November 22, 2024.
-
Alumis reports Q3 net loss of $93.1M; cash of $361.9M funds operations into 2026
Net loss of $93.1M in Q3 2024 vs $43.4M in Q3 2023; R&D expenses rose to $87.8M from $37.8M, including $23M milestone payment for FronThera acquisition.
-
Alumis Q2 net loss $56.5M, cash $209.5M; Phase 3 psoriasis trial initiated
Net loss $56.5M for Q2 2024 vs $36.3M in Q2 2023; R&D expense $48.6M (up from $32.8M).
-
Alumis closes $40M private placement of 2.5M shares
Completed sale of 2,500,000 shares of common stock for gross proceeds of $40M.
-
Alumis raises $40M in PIPE at $16/share from AyurMaya, tied to IPO
Agreed to sell 2.5M shares of common stock to AyurMaya at $16.00/share for $40M total.
-
Alumis files amended charter and bylaws upon IPO close on July 1, 2024
Filed amended and restated certificate of incorporation with Delaware Secretary of State.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.70 · Most common event other_material